40th week of 2009 patent applcation highlights part 50 |
Patent application number | Title | Published |
20090246137 | PYRIDYL DERIVATIVES AS CFTR MODULATORS - The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators. | 2009-10-01 |
20090246138 | METHOD OF IMAGING METABOLIC FUNCTION - A contrast imaging method e.g. of the T2* weighted “BOLD” type is adapted by use together with an oxygen challenge to provide imaging for the assessment of the metabolic responses of tissue over a period of time the method utilizing three components, oxygen, deoxyhaemoglobin, and oxyhaemoglobin together with time, to provide four variable parameters which allows oxygen to be used as a metabolic marker that can be utilized in an imaging evaluation of soft tissue and organs, e.g. in the study of viable tissue and organ function or dysfunction, which allows utility in diagnosis and assessment of conditions such as cancer, dementia, circulatory disorders, and autoimmune disorders. | 2009-10-01 |
20090246139 | Efficient methods to isolate effectors of proteins involved in olfactory or chemosensory pathways and efficient methods to use these effectors to alter organism olfaction, chemosensation, or behavior - This invention provides methods and compositions for identifying effectors, binding partners, or other molecules that interact with the proteins involved in the chemosensory pathway; examples of proteins involved in the olfactory pathway include odorant binding proteins (OBPs), sensory appendage proteins (SAPs), orthologs of the | 2009-10-01 |
20090246140 | METHODS FOR IDENTIFYING AND TARGETING AUTONOMIC BRAIN REGIONS - Disclosed herein are methods for identifying and targeting autonomic and autonomic-related brain regions. In one embodiment, a method of identifying a brain region in a patient comprises administering to the patient a targeting agent that activates or inhibits a brain region and imaging the brain region. | 2009-10-01 |
20090246141 | HIGHER FATTY ACID TRIESTER AND AMIDE DERIVATIVE HAVING DIETHYLENETRIAMINE-TYPE METAL CHELATE STRUCTURE - A compound having superior solubility and suitable for a liposome contrast medium selective for a lesion such as vascular diseases is provided which is represented by the following general formula (I) wherein R | 2009-10-01 |
20090246142 | Triggered Self-Assembly of Nanoparticles In Vivo - The present invention provides triggered self-assembly nanosystems. Such nanosystems comprise a population of triggered self-assembly conjugates, each conjugate comprising one or more monomeric units and one or more complementary binding moieties. In some embodiments, inventive nanosystems and conjugates can be used to treat and/or diagnose a disease, disorder, and/or condition. | 2009-10-01 |
20090246143 | NON-RADIOACTIVE TRACEABLE METAL ISOTOPE-ENRICHED NANOPARTICLES AND METHOD OF THEIR USE FOR DETERMINING BIODISTRIBUTION - Composition of non-radioactive traceable metal isotope-enriched nanoparticles, and methods of their use for determining in-vivo biodistribution are provided. The methods comprise the steps of: (a) introducing the nanoparticles into the biological material, wherein the nanoparticles comprise at least one inorganic core, and the inorganic core comprises at least two metal isotopes in a predetermined ratio; wherein at least one metal isotope is enriched non-radioactive traceable metal isotope and (b) determining the distribution of the nanoparticles in the biological material based on the predetermined ratio of the metal isotopes. | 2009-10-01 |
20090246144 | SYSTEM AND METHOD FOR INDIRECTLY MEASURING CALCIUM ION EFFLUX - A system and method for indirectly measuring calcium ion efflux from a cell of a subject by using manganese ions as a surrogate marker for calcium is disclosed. Manganese ion efflux is measured with a MEMRI T | 2009-10-01 |
20090246145 | Imaging Correlates of Neurogenesis With MRI - This invention provides a method for treating a mammalian subject afflicted with a disorder associated with reduced neurogenesis in the subject's hippocampal dentate gyrus which comprises administering to the subject a therapeutically effective amount of a compound which increases cerebral blood volume in the subject's hippocampal dentate gyrus by a percentage greater than that by which it increases the cerebral blood volume in the subject's hippocampal CA1 region, thereby treating the subject. | 2009-10-01 |
20090246146 | HALIDES IN THE TREATMENT OF PATHOGENIC INFECTION - The present invention relates to the use of halides and halide salts for the treatment of microbial infections, including those caused by bacteria, fungi and viruses. The present invention takes advantage of endogenous immune function and augments this system using a non-toxic and inexpensive reagent that can be delivered to mucosal surfaces, for example, orally, topically, opthalmically and via inhalation. | 2009-10-01 |
20090246147 | Delivery Of Antipsychotics Through An Inhalation Route - The present invention relates to the delivery of antipsychotics through an inhalation route. Specifically, it relates to aerosols containing antipsychotics that are used in inhalation therapy. In a method aspect of the present invention, an antipsychotic is delivered to a patient through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises an antipsychotic, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles with less than 5% antipsychotic drug degradation products. In a kit aspect of the present invention, a kit for delivering an antipsychotic through an inhalation route is provided which comprises: a) a thin coating of an antipsychotic composition and b) a device for dispensing said thin coating as a condensation aerosol. | 2009-10-01 |
20090246148 | Medicinal aerosols and methods of delivery thereof - The replacement of chlorofluorohydrocarbon propellants in medical aerosols is of the utmost importance to the pharmaceutical industry. A number of formulations have been investigated. | 2009-10-01 |
20090246149 | MEDICINAL AEROSOL FORMULATIONS - Use of particulate bulking agents having an extremely small mass median diameter of less than one micron, preferably less than 300 nm, in pharmaceutical aerosol formulations comprising a suspension of drug particles in a propellant. Examples of bulking agents include ascorbic acid, saccharides, polysaccharides, amino acids, organic and inorganic salts, urea, and propyliodone. | 2009-10-01 |
20090246150 | ANTIMICROBIAL COMPOSITION - The present invention relates to novel antimicrobial composition comprising a peptide which can be obtained from the milk protein casein or chemically synthesised or produced by recombinant DNA technology and a divalent cation. | 2009-10-01 |
20090246151 | Processes of Making Oral Compositions Containing Gel Networks - The present invention is directed towards a process for making oral compositions comprising gel networks. The gel networks are formed from a fatty amphiphile dispersion and swelling surfactant. The fatty amphiphile dispersion comprises one or more fatty amphiphiles, one or more dispersing surfactants, and one or more solvents. A gel network is formed when the fatty amphiphile dispersion is combined with the swelling surfactant. A method of preparing the fatty amphiphile dispersion and oral composition is included. | 2009-10-01 |
20090246152 | NARACTIN COMPOSITIONS FOR THE INHIBITION OF REACTIVE OXYGEN SPECIES - The invention relates to agents for sequestering serum aging factors, and methods for using the same. More particularly, the invention relates to agents termed herein “Naractin” to denote any one of several naturally-occurring arNOX inhibitors either present in | 2009-10-01 |
20090246153 | COSMETIC COMPOSITIONS FOR THE INHIBITION OF REACTIVE OXYGEN SPECIES - A composition and method having anti-aging properties is provided. The composition comprises an arNOX inhibitory agent present in a natural plant extract and is useful topically as a cosmetic. The symptoms of aging including lines, wrinkles, hyperpigmentation, dehydration, loss of elasticity, angioma, dryness, itching, telangietasias, actinic purpura, seborrheic keratoses and actinic keratoses. The invention may be used multiple times a day without deleterious effects. | 2009-10-01 |
20090246154 | USE OF AMINOPHENYLBENZOTRIAZOLE DERIVATIVES FOR PROTECTING HUMAN AND ANIMAL SKIN AND HAIR FROM THE HARMFUL EFFECTS OF UV RADIATION AND COSMETIC COMPOSITIONS THEREOF - Disclosed are-(2′-Hydroxy-4′-aminophenyl)benzotriazole derivatives of formula | 2009-10-01 |
20090246155 | Compositions and methods for personal care - Systems and methods for delivering personal care materials. Crystalline polymeric systems, referred to as CYC carriers, are associated with the cosmetic materials, through chemical bonding or through physical association. The crystallinity of the CYC carriers results from the presence of crystallizable side chains, for example long chain n-alkyl moieties, which results in relatively low and sharp melting temperatures. One class of CYC carriers, referred to as CYSC polymers, have a majority of the crystallizable side chains pendant from the polymer backbone. Another class of CYC carriers, referred to as ECC polymers, have a majority of the crystallizable side chains attached to terminal units of the polymer backbone. The ECC polymers can for example be obtained by modification of PLGA polymers. The CYC carriers in another class are non-polymeric. Some CYC carriers, referred to as CYC assemblies, have enhanced crystallinity as a result of the physical association of crystallizable moieties which are present in different types of molecule, for example between a polymer containing crystallizable moieties and a monomer containing crystallizable moieties. Preferably the CYC carrier is bioerodable. | 2009-10-01 |
20090246156 | ANTI-ACNE SUNSCREEN COMPOSITION - The present invention is directed to compositions for anti-acne sunscreen. The sunscreen composition has the unique ability to treat and prevent acne in addition to screen both UVA and UVB radiation. In particular, the sunscreen composition includes a sunscreen base, at least one UVA deactivator, at least one UVB deactivator, and at least one anti-acne agent. The UVA deactivator may be avobenzone and the UVB deactivator may be selected from one of the following oxybenzone, octisalate, octyl methoxycinnamate, or a mixture thereof. | 2009-10-01 |
20090246157 | METHOD OF QUENCHING ELECTRONIC EXCITATION OF CHROMOPHORE-CONTAINING ORGANIC MOLECULES IN PHOTOACTIVE COMPOSITIONS - The photostabilizing electronic excited state energy—particularly singlet state energy from a UV-absorbing molecule has been found to be readily transferred to (accepted by) α-cyanodiphenylacrylate compounds of formulas (I) and (V) having an alkoxy radical preferably in the four (para) position (hereinafter methoxycrylenes) on one or both of the phenyl rings: | 2009-10-01 |
20090246158 | ANTIOXIDANTS - The present invention relates to the use of compounds of the formula (I) where R stands for [lacuna] with radicals defined in the description, as antioxidants, to corresponding novel compounds and compositions, and to corresponding processes for the preparation of compounds and compositions. | 2009-10-01 |
20090246159 | Composition and Process for Treating Keratinous Substrates With At Least Two Immiscible Cosmetic Compositions - A process for treating a keratinous substrate involving: (a) providing at least a first composition having a continuous phase whose major ingredient has a solubility parameter corresponding to δ; (b) providing at least a second composition having a continuous phase whose major ingredient has a solubility parameter corresponding to δ′; and (c) combining (a) and (b) prior to, or during, their application onto the keratinous substrate, and wherein the difference between δ and δ′ is greater than 12, and wherein the major ingredient is chosen from a hydrophilic polar material, an organic non-polar material and an inorganic non-polar material. | 2009-10-01 |
20090246160 | OXIDIZING AQUEOUS DISPERSION FOR TREATING KERATIN FIBERS COMPRISING AT LEAST ONE NONIONIC AMPHIPHILIC HYDROPHOBIC COMPOUND - The subject of the present disclosure is a composition for treating keratin fibers comprising, in a cosmetically acceptable medium, at least one oxidizing agent; at least one nonionic amphiphilic hydrophobic compound which is solid at ambient temperature; and, optionally, at least one hydrophilic surfactant; wherein the weight ratio of the at least one hydrophilic surfactant to the at least one nonionic amphiphilic hydrophobic compound ranges from 0:1 to 0.16:1, on the condition that when the at least one hydrophilic surfactant is present, it must be chosen from cationic and zwitterionic hydrophilic surfactants; and further wherein the composition is in the form of an aqueous dispersion. | 2009-10-01 |
20090246161 | Cationic capped dimer acid polyesters in personal care applications - The present invention is directed to a series of cationic polyester compounds made from the reaction of (a) a difunctional hydroxy compound, specifically polyoxyalkylene glycols, (b) a difunctional carboxylic acid, specifically dimer acid and hydrogenated dimer acid, and (c) a capping cationic, hydroxyl containing compound which only contains one hydroxyl group. These compounds are very well suited to the preparation of products for the personal care market. | 2009-10-01 |
20090246162 | Treatment of Chronic Progressive Heart Failure - The invention provides a method for treating or preventing heart failure in a subject, which includes administering to the subject in need thereof a therapeutically effective amount of a Poloxamer (e.g., Poloxamer 188). | 2009-10-01 |
20090246163 | ANTI-STATIC SKIN PRODUCTS AND METHOD - An aqueous or non-aqueous preparation comprising cationic agents to neutralize a negative charge thereby relieving tension in the skin and preventing moisture from escaping. It relieves static-tension in the skin thereby reducing the distance between the pores. The difference between the Present Invention and other water based skin conditioners is the amount of cationic agents used. The Present Invention utilizes much more of these ingredients than other commercial products. This produces the unexpected result of neutralizing the charge on the skin and relieving tension, softening and moisturizing the skin. In its most basic form, it contains no moisturizing or other skin conditioning agents. These products can be added to the Present Invention, or alternatively, the Present Invention may be used as an additive to most currently available commercial aqueous and non-aqueous based skin moisturizers for a synergistic skin softening effect. | 2009-10-01 |
20090246164 | TISSUE ADHESION - A method of adhering biological tissue that includes applying a bio-degradable adhesive to the tissue. The adhesive includes a moisture-curable, isocyanate-functional component prepared by reacting (a) a multi-functional isocyanate component and (b) a multi-functional active hydrogen component that includes at least 30% by weight, based upon the total weight of the multi-functional active hydrogen component, of a multi-functional active hydrogen reactant having an equivalent weight less than 100. The ratio R of active hydrogen groups to isocyanate groups can be less than 1.0. | 2009-10-01 |
20090246165 | Disinfectant with Quarternary Ammonium Polymer and Copolymers - An alcohol-soluble, water-insoluble, disinfectant composition and a method of using the same for disinfecting and for providing a prolonged antimicrobial property to a variety of surfaces, including skin. The composition comprises an antimicrobial polymer that is capable of imparting an antimicrobial property to a surface without the use of a metal or metal-containing compound. The composition is applied to a surface and allowed to evaporate leaving a coating of antimicrobial polymer. | 2009-10-01 |
20090246166 | Pearl Like Polyvinyl Alcohol Particles, Production Process Thereof and Temporary Vascular Embolic Agent - The embodiments provide a temporary vascular embolic agent temporarily blocking the blood vessel in vivo, having appropriate dissolution speed suitable for use in the blood vessel in which blood flow is fast and being more superior in the passing property of a catheter and the controllability of embolization time than conventional one. The embolization of the blood vessel led to cardiac muscle in which blood flow speed is fast is enabled by the temporary vascular embolic agent of the present invention using the pearl like polyvinyl alcohol (PVA) particles having 0.1 to 2% by mol of a 1,2-diol configuration unit and having a saponification degree of at least 99% by mol. | 2009-10-01 |
20090246167 | STIMULI-RESPONSIVE SYSTEMS FOR CONTROLLED DRUG DELIVERY - A method of delivering a therapeutic agent by providing a cross-linked polymer encapsulating the therapeutic agent to a site in a patient. The degradation rate of the cross-linked polymer is correlated with a local concentration of an indicator, and the therapeutic agent is released as the cross-linked polymer degrades. | 2009-10-01 |
20090246168 | ANTITUMORAL TREATMENTS - The present invention relates to combinations of aplidine or aplidine analogues with other antitumoral agents, and the use of these combinations in the treatment of cancer, in particular in the treatment of lung cancer, breast cancer, colon cancer, prostate cancer, renal cancer, melanoma, multiple myeloma, leukemia and lymphoma. | 2009-10-01 |
20090246169 | INDOLOPYRIDINES AS EG5 KINESIN MODULATORS - Compounds of a certain formula I, in which R1, R2, R3, R4, R5 and R6 have the meanings indicated in the description, are effective compounds with anti-proliferative and/or apoptosis inducing activity. | 2009-10-01 |
20090246170 | Therapeutic Agent For Alzheimer's Disease - The present invention provides novel therapeutic methods and agents for treating Alzheimer's disease. Specifically, the present invention relates to anti-inflammatory cytokines, anti-inflammatory cytokine genes, negative-strand RNA viral vectors carrying an anti-inflammatory cytokine gene, which are used for treating Alzheimer's disease or developing therapeutic agents for Alzheimer's disease. The present invention also provides pharmaceutical compositions for treating or preventing Alzheimer's disease, which comprise the cytokines or vectors. The present invention further provides methods for treating Alzheimer's disease, which comprise the step of administering an anti-inflammatory cytokine, or a vector such as a negative-strand RNA viral vector carrying an anti-inflammatory cytokine gene. The present invention enables novel gene therapies for Alzheimer's disease. | 2009-10-01 |
20090246171 | AUTOMATIC SYSTEM FOR DOSE CONTROL IN TREATING HEPATITIS C USING INFUSION PUMPS - According to one embodiment, a method of controlling a plurality of treatment dosages for Hepatitis C includes: setting a first dosage level to cause a viral load of a subject user to reduce at a rate over time; determining, after setting the first dosage level, if the rate of the viral load reduction changes over time by a first threshold; setting a second dosage level in response to determining that the rate of the viral load reduction changes by the first threshold; determining, after setting the second dosage level, if the rate of the viral load reduction changes over time by a second threshold; setting a third dosage level in response to determining that the rate of the viral load reduction changes by the second threshold; and maintaining the second dosage level in response to determining that the rate of the viral load reduction has not changed by the second threshold. | 2009-10-01 |
20090246172 | COMPOSITIONS COMPRISING EPOTHILONES AND THEIR USE FOR THE TREATMENT OF CARCINOID SYNDROME - Use of a compound formula I | 2009-10-01 |
20090246173 | TREATMENT WITH ANTI-VEGF ANTIBODIES - This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents. | 2009-10-01 |
20090246174 | TREATMENT FOR CUTANEOUS T CELL LYMPHOMA - The present invention provides method for treating a patient with cutaneous T cell lymphoma (CTCL). Generally, the methods include administering to the patient an IRM compound in an amount effective to ameliorate at least one symptom or clinical sign of CTCL. In some embodiments, the methods also include administering to the patient a priming dose of a Type I interferon. In another aspect, the invention provides methods of increasing a cell-mediated immune response of a cell population that includes cells affected by cutaneous T cell lymphoma. Generally, the methods include contacting the cell population with an IRM compound in an amount effective to increase at least one cell-mediated immune activity of the cell population. In some embodiments, the methods include contacting the cell population with a priming dose of a Type I interferon. | 2009-10-01 |
20090246175 | THERAPEUTIC USE OF SCIN, A STAPHYLOCOCCAL COMPLEMENT INHIBITOR IN INFLAMMATORY DISEASES - The present invention relates to the use of the staphylococcal complement inhibitor (SCIN) or a homologue thereof, or a derivative or a fragment of SCIN or the SCIN homologue for the preparation of a medicament for intervening with C3 and C5 convertases. The medicament is in particular intended for inhibiting activation of the classical and/or the alternative pathway of complement. More in particular, the medicament is for treating indications that involve complement activation via the classical and/or alternative pathway. | 2009-10-01 |
20090246176 | METHOD FOR TREATING DIABETES MELLITUS, OBESITY, CHRONIC FATIGUE, AGING, AND OTHER MEDICAL CONDITIONS BY UTILIZING MODIFIED VIRUS VIRIONS TO INSERT MESSENGER RIBONUCLEIC ACID MOLECULES INTO CELLS - The common link between diabetes mellitus, obesity, chronic fatigue and even aging may be related to deficiencies involving a body's metabolism of glucose and the ability to optimally conduct the necessary biologic processes of aerobic respiration. Utilizing a modified form of virus to deliver to cells in the body the messenger RNA molecules needed to construct insulin receptors and generate the enzymes that participate in the processes of glycolysis, the tricarboxylic acid cycle, oxidative phosphorylation and anaerobic respiration will lead to greater utilization of blood glucose and a more efficient and sustained production of the energy molecules that fuel the metabolic processes of the cell. Greater utilization of blood glucose will correct problems associated with diabetes, obesity, chronic fatigue, and aging. | 2009-10-01 |
20090246177 | MEGASPHAERA ELSDENII STRAIN AND ITS USES - This invention relates to a novel strain of | 2009-10-01 |
20090246178 | CD56 POSITIVE HUMAN ADULT PANCREATIC ENDOCRINE PROGENITOR CELLS - The invention relates to the discovery of a selective cell surface marker that permits the selection of a unique subset of pancreatic stems cells having a high propensity to differentiate into insulin producing cells or into insulin producing cell aggregates. | 2009-10-01 |
20090246179 | METHOD OF TREATING MYOCARDIAL INJURY - A method of treating a myocardial injury of a subject includes administering a population of at least one of mesenchymal stem cells (MSCs), multipotent adult progenitor cells (MAPCs), embryonic stem cells (ESCs), induced pluripotent stem cells (iPSs), which have down-regulated expression of disabled-2 (Dab2), to the subject. | 2009-10-01 |
20090246180 | HYPOXIA INDUCING FACTORS AND USES THEREOF FOR INDUCING ANGIOGENESIS AND IMPROVING MUSCULAR FUNCTIONS - This invention provides HIF-3α nucleic acid and sequences. Also provided are methods for using HIF-3α nucleic acids, proteins, fragments, antibodies, probes, and cells, to characterize HIF-3α, modulate HIF-3α cellular levels, induce angiogenesis, improve muscular function, and treat coronary and cardiac diseases in mammals. | 2009-10-01 |
20090246181 | THERAPEUTIC COMPOSITION FOR ATOPIC DERMATITIS - A novel type of therapeutic agent, human mesenchymal stem cells, and a composition containing the same for the treatment of atopic dermatitis is disclosed. A method for the treatment of atopic dermatitis in patient is also disclosed. | 2009-10-01 |
20090246182 | METHOD FOR CULTURING CELLS DERIVED FROM THE ADIPOSE TISSUE AND USES THEREOF - The invention concerns a method for culturing cells derived from the adipose tissue and in particular the stromal vascular fraction (SVF) to induce formation of cardiomyocytes, the use of the cells obtained by said culture method to reconstitute an ischemized cardiac zone, in particular following an infarction, as well as a pharmaceutical composition containing said cells. The method for obtaining cardiac cells comprises at least the following steps: a) selecting cardiomyogenic cells from the stromal vascular fraction (SVF); b) culturing the cells selected at step a) in a liquid medium optimized for expanding ex vivo the cardiomyogenic cells; c) maintaining and expanding said cells by successive passes in the liquid medium; and d) obtaining cardiac cells. | 2009-10-01 |
20090246183 | eNOS mutations useful for gene therapy and therapeutic screening - The present invention relates to new NOS variants or mutants which contain structural alterations in the site of Akt dependent phosphorylation. The altered NOS proteins or peptides, especially the human eNOS proteins or peptides, Akt proteins or polypeptides and their encoding nucleic acid molecules are useful as gene therapy agents for the treatment of diseases including post angioplasty restenosis, hypertension, atherosclerosis, heart failure, diabetes and diseases with defective angiogenesis. NOS proteins and peptides are also useful in methods of screening for agents which modulate NOS activity. | 2009-10-01 |
20090246184 | DELIVERY VEHICLE FOR PROBIOTIC BACTERIA COMPRISING A DRY MATRIX OF POLYSACCHARIDES, SACCHARIDES AND POLYOLS IN A GLASS FORM AND METHODS OF MAKING SAME - The disclosure relates to a solid glass matrix of polysaccharide, saccharides and polyols as delivery vehicle for preservation and post gastric administration of a probiotic. The delivery vehicle is capable of releasing the probiotic at their site of action. The present invention further includes methods of making and using the solid glass matrix delivery vehicle of the invention. | 2009-10-01 |
20090246185 | CARDIAC DYSFUNCTION-AMELIORATING AGENT OR CARDIAC FUNCTION-MAINTAINING AGENT - An object of the present invention is to provide a highly safe oral composition superior in a cardiac dysfunction-ameliorating or cardiac function-maintaining action. The present inventors have conducted intensive studies in an attempt to solve the aforementioned problems and found that use of, particularly, reduced coenzyme Q10 from among highly safe coenzyme Q affords a composition useful for amelioration of cardiac dysfunction and maintenance of cardiac function. Accordingly, the present invention provides a cardiac dysfunction-ameliorating agent or cardiac function-maintaining agent containing reduced coenzyme Q as an active ingredient, and a pharmaceutical product, a food, an animal drug, a feed and the like, which contain the agent. | 2009-10-01 |
20090246186 | AGENT FOR IMPROVING NERVOUS SYSTEM CELL FUNCTIONS - The present invention aims to activate neural cells in brain, and further provide a useful composition having an action to protect intracerebral neural cells from external and internal stresses. | 2009-10-01 |
20090246187 | PROCESS FOR CONCENTRATION OF A POLYPEPTIDE - The present invention comprises a method of concentrating a composition comprising a polypeptide of interest and the use of such a concentrated composition for the treatment of diseases in mammals, in particular by subcutaneous injection. | 2009-10-01 |
20090246188 | Method for Production of a Bioengineered Form of Tissue Plasminogen Activator - The present invention relates to the recombinant method used for the production of soluble form of human tissue plasminogen activator variant. In this variant the threonine at position 103 of the endogenous tissue plasminogen activator is replaced by an asparagine leading to a new glycosylation site. At position 117 of the endogenous tissue plasminogen activator asparagine has been replaced by glutamine, leading to the removal of an N linked glycosylation site. At position 296-299 the amino acids lysine, histidine, arginine, and arginine have been replaced by four alanine amino acids. The invention further relates to the de novo synthesis of the nucleic acid sequence encoding tissue plasminogen activator, transformation of the constructed nucleic acid sequences into competent bacteria and sub-cloning of the same into mammalian expression vectors for the expression of the desired protein. DNA constructs comprising the control elements associated with the gene of interest have been disclosed. The recombinant human tissue plasminogen activator, according to the invention, and the salts and functional derivatives thereof, may comprise the active ingredient of pharmaceutical compositions for treatment of treatment of heart attack and stroke patients. These compositions are yet another aspect of the present invention. | 2009-10-01 |
20090246189 | Methods for Promoting Neurite Outgrowth and Survival of Dopaminergic Neurons - The present invention relates generally to methods for promoting regeneration, outgrowth and survival of dopaminergic neurons comprising contacting said dopaminergic neurons with an effective amount of a composition comprising an Sp35 antagonist. Additionally, the invention is related generally to methods of treating various diseases, disorders or injuries associated with dopaminergic neuronal degeneration or death by administration of an Sp35 antagonist. | 2009-10-01 |
20090246190 | ANTI-VEGF ANTIBODY - An antibody is provided. In certain cases, the antibody comprises: a) a heavy chain variable domain that comprises CDR regions that are substantially identical to the heavy chain CDR regions of a selected antibody and b) a light chain variable domain that comprises CDR regions that are substantially identical to the light chain CDR regions of the selected antibody, where the antibody binds a selected target. | 2009-10-01 |
20090246191 | Preparation of Purified Covalently Cross-linked Abeta Oligomers and Uses Thereof - The present invention provides a method of purifying cross-linked oligomers. The purified cross-linked oligomers are useful as immunogen for generating and isolating cross-linked oligomer reactive antibodies. The cross-linked oligomer reactive antibodies are useful for detecting amyloid deposition and for diagnosing and treating diseases and conditions associated with amyloid deposition. | 2009-10-01 |
20090246192 | 1D05 PCSK9 antagonists - Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure. | 2009-10-01 |
20090246193 | INACTIVATING ORGANISMS USING CARBON DIOXIDE AT OR NEAR ITS SUPERCRITICAL PRESSURE AND TEMPERATURE CONDITIONS - Whole organisms are inactivated by at least a factor of 10 | 2009-10-01 |
20090246194 | ERYTHROPOIETIN ANALOG-IgG FUSION PROTEINS - Erythropoietin analog-human IgG fusion protein (EPOa-IgG) fusion protein and methods of making and using the fusion protein. | 2009-10-01 |
20090246195 | ANTI-CD19 ANTIBODY THERAPY FOR TRANSPLANTATION - The invention relates to immunotherapeutic compositions and methods for the treatment and prevention of GVHD, humoral rejection, and post-transplantation lymphoproliferative disorder in human subjects using therapeutic antibodies that bind to the human CD19 antigen and that preferably mediate human ADCC. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG1 or IgG3 human isotype. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG2 or IgG4 human isotype that preferably mediate human ADCC. The present invention also relates to pharmaceutical compositions comprising chimerized anti-CD19 antibodies of the IgG1, IgG2, IgG3, or IgG4 isotype that mediate human ADCC. In preferred embodiments, the present invention relates to pharmaceutical compositions comprising monoclonal human, humanized, or chimeric anti-CD19 antibodies. | 2009-10-01 |
20090246196 | COMBINED TARGETED THERAPY FOR THE TREATMENT OF PROLIFERATIVE DISEASE - A method of treating an individual comprising: evaluating the disease state of said individual through quantitative and/or qualitative assays; administering in amounts sufficient to treat said disease at least three agents wherein at least one agent is an inhibitor of the human epidermal receptor pathway, at least one agent is signal transduction inhibitor and at least one agent is an angiogenesis inhibitor and; reevaluating the disease state of said individual presenting through quantitative and/or qualitative assays. A composition comprising a first agent that is an inhibitor of the human epidermal receptor pathway, a second agent that is an angiogenesis inhibitor and a third agent that is an inhibitor of Akt wherein said first agent, second agent, third agent and combinations thereof are present in amounts that when administered to an individual in a diseased state are sufficient to treat said disease. | 2009-10-01 |
20090246197 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH INCREASED ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY (ADCC) - The present invention is directed to a pharmaceutical composition comprising: (A) a type II anti-CD20 antibody with increased antibody dependent cellular cytotoxicity (ADCC); and (B) a chemotherapeutic agent selected from the group consisting of: cyclophosphamide, vincristine and doxorubicine. | 2009-10-01 |
20090246198 | MAPK/ERK KINASE INHIBITORS AND METHODS OF USE THEREOF - Compounds of the following formula are provided: | 2009-10-01 |
20090246199 | THERAPEUTIC METHODS FOR INHIBITING TUMOR GROWTH WITH DLL4 ANTAGONISTS - Disclosed is a therapeutic method for inhibiting development or growth of tumors that are resistant to the blockade of delta-like ligand 4 (Dll4), or vascular endothelial growth factor (VEGF), or to other therapeutic agents, by administering the combination of Dll4 antagonist and VEGF antagonist. The combined administration of these two agents, concurrently or sequentially, exhibits synergistic effects on blood vessel development and growth, thereby more effectively inhibiting the tumor growth than an administration of either agent alone. The Dll4 antagonist can be an anti-Dll4 antibody or antibody fragment capable of inhibiting the binding of Dll4 to a Notch receptor, or a fusion protein comprising the extracellular domain of Dll4 or a soluble Notch receptor, or a fragment thereof, fused to a multimerizing component. The VEGF antagonist can be a VEGF trap, anti-VEGF antibody or antibody fragment capable of inhibiting the binding of VEGF to a VEGF receptor. | 2009-10-01 |
20090246200 | Anthrax carbohydrates, synthesis and uses thereof - The present invention presents the isolation, characterization and synthesis of oligosaccharides of | 2009-10-01 |
20090246201 | Substances - The present invention provides a homologue to heparanase which is present in three splice variants. | 2009-10-01 |
20090246202 | Human Endokine Alpha and Methods of Use - The present invention concerns a novel member of the tumor necrosis factor (TNF) family of cytokines. In particular, isolated nucleic acid molecules are provided encoding the endokine alpha protein. Endokine alpha polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. Also provided are diagnostic and therapeutic methods concerning TNF family-related disorders. | 2009-10-01 |
20090246203 | METHOD FOR IMMUNOADSORPTION BY MEANS OF AUTOANITGENS - The invention relates to a novel method for immunoadsorption therapy of human autoimmune diseases by means of immobilized or fixed autoantigens. | 2009-10-01 |
20090246204 | USE OF A CD28 BINDING SUBSTANCE FOR MAKING A PHARMACEUTICAL COMPOSITION - The invention relates to the use of a CD28-specific superagonistic monoclonal antibody (mAb) or of a mimicry compound hereto for making a pharmaceutical composition for the induction and/or multiplication of regulatory T cells. | 2009-10-01 |
20090246205 | Inhibition of macrophage-stimulating protein receptor (ron) - The present invention relates to methods for treatment of tumors and other diseases in a mammal comprising administration of antibodies specific for Macrophage-Stimulating Protein Receptor (“MSP-R” or “RON”). The present invention further provides for compositions comprising antibodies or antibody fragments specific for RON, including human antibodies, that inhibit RON activation. | 2009-10-01 |
20090246206 | BISPECIFIC BINDING AGENTS FOR MODULATING BIOLOGICAL ACTIVITY - Methods for improving the specific binding ability of bispecific binding compositions are described. The bispecific binding compositions are able to target cells by a high affinity targeting domain to a target cell surface marker and a low affinity binding domain that binds specifically to a second cell surface marker, wherein the binding of each domain to its respective cell surface marker increases or decreases, as desired, the biological activity of the respective cell surface markers. The invention further provides bispecific binding agents for use in the methods, as well as uses for the agents. | 2009-10-01 |
20090246207 | Calf Biologic Anti-Scour Supplement (CBAS) - A composition for prevention digestive infection in a ruminant infant is disclosed. The composition consists of: a predetermined amount of yolk immunoglobulin (IgY) for a target bacteria; a predetermined amount of a plurality of hormones and a predetermined amount of a plurality of proteins, wherein said plurality of hormones comprises of a group consisting of bovine insulin (bIns), bovine growth hormone (bGH), and bovine prolactine (bPrl), and wherein said plurality of proteins comprises of a group consisting of, bovine insulin like growth factor (bIGF), lactoferrin factor (LF), and transferring factor (TF); and a predetermined amount of bacterial biomass, wherein said bacterial biomass comprises of a group consisting of bacterial DNA, bacterial RNA, bacterial protein, and bacterial polysaccharides. | 2009-10-01 |
20090246208 | METHODS FOR PREVENTING AND TREATING CANCER METASTASIS AND BONE LOSS ASSOCIATED WITH CANCER METASTASIS - Methods for preventing and treating osteolysis, cancer metastasis and bone loss associated with cancer metastasis by administering an M-CSF-antagonist in combination with a therapeutic agent to a subject are provided. | 2009-10-01 |
20090246210 | IL-1Beta Binding Antibodies and Binding Fragments thereof - An IL-1β binding antibody or IL-1β binding fragment thereof comprising the amino acid sequence of SEQ ID NO: 26 and SEQ ID NO: 11, and related nucleic acids, vectors, cells, and compositions, as well as method of using same to treat or prevent a disease. IL-1β binding antibodies or IL-1β binding fragments thereof are provided which have desirable affinity and potency. | 2009-10-01 |
20090246211 | Molecular constructs suitable for targeted conjugates - The present invention relates generally to effective drug-linker constructs suitable for conjugation with ligands. The present invention also discloses methods of conjugating these constructs with peptides to form the compound of formula I. These methods are readily extended to any hydroxyl, amine or sulfur bearing biologically active molecules. | 2009-10-01 |
20090246212 | DEVELOPMENT OF METHOD FOR SCREENING FOR DRUG CAPABLE OF IMPROVING PRODUCTION OF REGULATORY T CELLS AND METHOD FOR PRODUCING REGULATORY T CELLS USING IMMUNOSUPPRESSIVE MACROLIDE ANTIBIOTIC - The present invention provides a screening method for a compound capable of inducing regulatory T cells, comprising the following steps: | 2009-10-01 |
20090246213 | VACCINE COMPRISING A POLYNUCLEOTIDE ENCODING AN ANTIGEN RECOGNIZED BY A CD4+ HELPER T-CELL AND A POLYNUCLEOTIDE ENCODING A TUMOR SPECIFIC OR ASSOCIATED ANTIGEN RECOGNIZED BY A CD8+ CTL - The present invention relates to a DNA vaccine for developing tumor-specific immunity. Specifically, the invention relates to a DNA vaccine comprising antigens recognized by CD4 | 2009-10-01 |
20090246214 | FUSION PROTEINS CONTAINING RECOMBINANT CYTOTOXIC RNASES - Recombinant immunotoxins containing a cytotoxic RNAse fused to an antibody or antibody fragment may be produced in mammalian cell culture. Surprisingly, immunotoxins containing a cytotoxic RNAse fused to the N-terminus of one antibody variable domain can be prepared and retain the ability to specifically bind antigen. The immunotoxins may be used in a variety of therapeutic methods for treating diseases or syndromes associated with unwanted or inappropriate cell proliferation or activation. | 2009-10-01 |
20090246215 | Amyloid beta1-6 antigen arrays - The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array, and in particular an Aβ1-6 peptide-VLP-composition. More specifically, the invention provides a composition comprising a virus-like particle and at least one Aβ1-6 peptide bound thereto. The invention also provides a process for producing the conjugates and the ordered and repetitive arrays, respectively. The compositions of the invention are useful in the production of vaccines for the treatment of Alzheimer's disease and as a pharmaccine to prevent or cure Alzheimer's disease and to efficiently induce immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context. | 2009-10-01 |
20090246216 | NOVEL ATTENUATED POLIOVIRUS - A novel and stable attenuated poliovirus, which replicates in neuroblastoma cells, is produced by engineering an indigenous replication element (cre), into the 5′ non-translated genomic region and inactivating the native cre element located in the coding region of 2C (mono-crePV). The stably attenuated poliovirus replicates in a neuroblastoma model (Neuro-2a | 2009-10-01 |
20090246217 | Novel Peptides for Treating and Preventing Immune-Related Disorders, Including Treating and Preventing Infection by Modulating Innate Immunity - In one aspect, the present invention provides isolated novel peptides that can be used to modulate innate immunity in a subject, and/or for the treatment of an immune-related disorder, including treating and preventing infection by modulating innate immunity. Also provided are an agent reactive with this peptide, a pharmaceutical composition that includes the peptide, an isolated nucleic acid molecule encoding the peptide, a recombinant nucleic acid construct that includes the nucleic acid molecule, at least one host cell comprising the recombinant nucleic acid construct, and a method of producing the peptide using the host cell. The present invention further provides a method for treating and/or preventing infection in a subject by administering the peptide of the invention to the subject, thereby modulating innate immunity in the subject. Additionally, the present invention provides a method for predicting whether a subject would be responsive to treatment with a peptide of the invention. | 2009-10-01 |
20090246218 | S. AUREUS FIBRINOGEN BINDING PROTEIN GENE - The isolation of genes and proteins from | 2009-10-01 |
20090246219 | NOVEL SURFACE EXPOSED HAEMOPHILUS INFLUENZAE PROTEIN (PROTEIN E; pE) - The present invention relates to a surface exposed protein (protein E; pE), a virulence factor, which can be detected in | 2009-10-01 |
20090246220 | CONSTRUCTS FOR ENHANCING IMMUNE RESPONSES - Chimeric protein constructs including a herpesvirus glycoprotein D (gD) and a heterologous polypeptide that interact with herpes virus entry mediator (HVEM) and enhance and enhance an immune response against the heterologous polypeptide and methods for their use are provided. | 2009-10-01 |
20090246221 | IMMUNOMODULATORY AGENTS AND METHODS OF USE - An antisense oligonucleotide compound, composition, vaccine and methods for treating a variety of conditions characterized by up-regulation of IL-10 in a mammalian subject are disclosed. The compound (i) is composed of morpholino subunits and phosphorus-containing intersubunit linkages joining a morpholino nitrogen of one subunit to a 5′ exocyclic carbon of an adjacent subunit, (ii) is capable of uptake by monocytes, lymphocytes, and dendritic cells in a mammalian subject, (iii) contains between 10-40 nucleotide bases, and (iv) has a base sequence effective to hybridize to at least 12 contiguous bases of a target sequence contained in an exon-2 or exon-4 slice site region of human IL-10 pre-mRNA. | 2009-10-01 |
20090246222 | Live Attenuated Bordetella Strains as a Single Dose Vaccine Against Whooping cough | 2009-10-01 |
20090246223 | Inactivated Chimeric Vaccines and Related Methods of Use - Embodiments of the present invention generally provide an inactivated chimeric virus vaccine and/or immunogenic composition for the treatment or prevention of viral infection. Further, various other embodiments of the present invention generally relate to methods of preventing and treating virus infection in such animals with the inactivated vaccine and/or immunogenic composition. Other embodiments comprise methods of preparing a vaccine or immunogenic composition for the treatment or prevention of viral infection in such animals. | 2009-10-01 |
20090246224 | VACCINE - The present invention relates to the field of neisserial vaccine compositions, their manufacture, and the use of such compositions in medicine. More particularly it relates to processes of making novel engineered meningococcal strains which are more suitable for the production of neisserial, in particular meningococcal, outer-membrane vesicle (or bleb) vaccines. Advantageous processes and vaccine products are also described based on the use of novel LOS subunit or meningococcal outer-membrane vesicle (or bleb) vaccines which have been rendered safer and more effective for use in human subjects. | 2009-10-01 |
20090246225 | Methods of Producing Influenza Vaccine Compositions - Methods and compositions for the optimization of production of influenza viruses suitable as influenza vaccines are provided. | 2009-10-01 |
20090246226 | Avian vaccines possessing a positive marker gene - The present invention provides a poultry vaccine containing a positive marker gene. More specifically, recombinant turkey herpesvirus modified by the presence of an extraneous antigen gene that may be used as a positive marker to identify and track vaccinated animals is provided. When inoculated into host animals, a poultry vaccine comprising the recombinant turkey herpesvirus provided in the present invention can elicit serological immune responses to the marker gene product that may be detected by serological assays such as enzyme-linked immunosorbent assay and serum agglutination test, thus enabling easy identification and tracking of vaccinated animals. | 2009-10-01 |
20090246227 | METHODS OF USE FOR HSV-1 AND HSV-2 VACCINES - This invention provides methods of treating, suppressing, inhibiting, reducing an incidence, reducing the pathogenesis of, ameliorating the symptoms of, or ameliorating the secondary symptoms of a primary or recurring Herpes Simplex Virus (HSV) infection, or prolonging the latency to a relapse of an HSV infection, and disorders and symptoms associated with same and inducing an anti-HSV immune response in a subject comprising the step of contacting the subject with a composition comprising a mutant HSV strain comprising an inactivating mutation in a Us8 gene, followed by a second contacting with the composition. | 2009-10-01 |
20090246228 | Moraxella catarrhalis Proteins - Novel antigens of | 2009-10-01 |
20090246229 | Subunit vaccine of pasteurella multocida in veterinary uses - The present invention declaims the use of | 2009-10-01 |
20090246230 | Compositions and methods for inducing tumor resistance - The invention provides a combined whole cell tumor vaccine for inducing tumor resistance in patients and treating cancer. | 2009-10-01 |
20090246231 | Formulations containing borojo - The present invention relates to a cosmetic and skin care formulation comprising: borojo; and at least one humectant; and at least one emollient. The present invention also provides for a dietary and nutritional supplement comprising: borojo; at least one mineral; at least one vitamin and at least one protein. | 2009-10-01 |
20090246232 | Pharmaceutical composition - Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes. | 2009-10-01 |
20090246233 | Treatment of Gastroparesis and Nonulcer Dyspepsia With GABAB Agonists - The present invention relates to formulations comprising a therapeutically effective amount of baclofen or (R)-baclofen, or pharmaceutically acceptable salts thereof, and methods of their use. The present formulations and methods are designed to release a therapeutic amount of baclofen in a manner that maximizes its therapeutic effect. The methods and formulations are especially suitable for treating gastroparesis and nonulcer dyspepsia. | 2009-10-01 |
20090246234 | Therapeutic Treatment Using Niacin for Skin Disorders - Niacin and/or niacinamides are incorporated with liposomes in therapeutic compositions for topical application to prevent or alleviate the conditions and symptoms of skin aging and other histological disorders. In particular, niacin and/or niacinamides are combined with liposomes to increase the penetration of the niacin and/or niacinamides into the deep epidermis and dermis skin layers and to provide hydration of the skin during treatment. | 2009-10-01 |
20090246235 | POLYAMIDE POROUS SPHERICAL PARTICLE - Polyamide porous spherical particles having a number-average particle diameter of 2 to 30 μm, a BET specific surface area of 100 to 80,000 m | 2009-10-01 |
20090246236 | Hair Care Compositions Comprising Sucrose Polyesters - A hair care composition having a conditioning active comprising a sucrose polyester having a melting point greater than about 30° C., an IBAR greater than about 5, an IV of about 3 to about 70, and an aqueous carrier, and may further comprise optional ingredients including but not limited to, silicone, cationic polymers, and fatty alcohols. The composition can also comprise a blend of sucrose polyesters, wherein the blend comprises two or more sucrose polyesters, wherein at least one sucrose polyester has a melting point greater than about 30° C., an IBAR greater than about 5, an IV of about 3 to about 70, and at least one sucrose polyester has an IBAR between about 1 and about 8, and an IV between about 1 and about 135, and wherein the sucrose polyester blend has an IBAR of at least 5 and an IV of about 1 and about 135. | 2009-10-01 |
20090246237 | FLUID POWDER DENTIFRICE FOR THE TREATMENT OF THE GUMS, AND A CORRESPONDING PRODUCTION METHOD - The dentifrice powder comprises grains of ground pumice stone coated with particles of a dry extract of fruit tree leaves, in particular pawpaw leaves, and is preferably obtained by carrying out a method comprising the following steps:
| 2009-10-01 |